1
|
Al-Ibraheem A, Allouzi S, Abdlkadir AS, Mikhail-Lette M, Al-Rabi K, Ma'koseh M, Knoll P, Abdelrhman Z, Shahin O, Juweid ME, Paez D, Lopci E. PET/CT in leukemia: utility and future directions. Nucl Med Commun 2024:00006231-990000000-00289. [PMID: 38646840 DOI: 10.1097/mnm.0000000000001846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease. However, its role in various clinical scenarios in leukemia remains unacknowledged. Despite their less common use, some novel PET/CT radiotracers are being researched for potential use in specific scenarios in leukemia patients. Therefore, the objectives of this review are to provide a thorough assessment of the current applications of [18F]FDG PET/CT in the staging and monitoring of leukemia patients, as well as the potential for an expanding role of PET/CT in leukemia patients.
Collapse
Affiliation(s)
- Akram Al-Ibraheem
- Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC)
- Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan
| | - Sudqi Allouzi
- Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC)
| | | | - Miriam Mikhail-Lette
- Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Kamal Al-Rabi
- Department of Medical Oncology, King Hussein Cancer Center (KHCC), Amman, Jordan
| | - Mohammad Ma'koseh
- Department of Medical Oncology, King Hussein Cancer Center (KHCC), Amman, Jordan
| | - Peter Knoll
- Dosimetry and Medical Radiation Physics Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Zaid Abdelrhman
- Department of Medical Oncology, King Hussein Cancer Center (KHCC), Amman, Jordan
| | - Omar Shahin
- Department of Medical Oncology, King Hussein Cancer Center (KHCC), Amman, Jordan
| | - Malik E Juweid
- Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan
| | - Diana Paez
- Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Egesta Lopci
- Department of Nuclear Medicine, IRCCS - Humanitas Clinical and Research Hospital, Rozzano (MI), Italy
| |
Collapse
|
2
|
Cailly L, Gruchet C, Maitre E, Guidez S, Delwail V, Systchenko T, Moya N, Sabirou F, Levy A, Bobin A, Gardeney H, Nsiala L, Vonfeld M, Chacon A, Pichon A, Bouyer S, Baslé C, Dindinnaud E, Chomel J, Raimbault A, Borde‐Mougenot F, Troussard X, Tomowiak C. Hairy cell leukemia with isolated bone lesions. Clin Case Rep 2023; 11:e7343. [PMID: 37207087 PMCID: PMC10188895 DOI: 10.1002/ccr3.7343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2023] [Revised: 03/24/2023] [Accepted: 04/28/2023] [Indexed: 05/21/2023] Open
Abstract
Key Clinical Message 18F-FDG PET/CT has clinical relevance in HCL at diagnosis and for the follow-up of patients treated, especially in case of atypical presentations such as bone involvements (which are probably underestimated) and poor bone marrow infiltration. Abstract Bone lesions are rarely reported in Hairy Cell Leukemia (HCL). We report two BRAFV600E mutated HCL patients presented bone lesions at foreground, poor bone marrow involvement, and the important role 18F-FDG PET/CT played in their management. We discuss the crucial role that 18F-FDG PET/CT could play in HCL routine practice.
Collapse
Affiliation(s)
- Laura Cailly
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Cécile Gruchet
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Elsa Maitre
- Department of Hematology, CHU Cote de NacreUniversity HospitalCaenFrance
| | - Stephanie Guidez
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Vincent Delwail
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Thomas Systchenko
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Niels Moya
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Florence Sabirou
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Anthony Levy
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Arthur Bobin
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Hélène Gardeney
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Laly Nsiala
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Mathilde Vonfeld
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Aurélia Chacon
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Aurélien Pichon
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| | - Sabrina Bouyer
- Department of Biology, CHU La MiletrieUniversity HospitalPoitiersFrance
| | - Caroline Baslé
- Department of Biology, CHU La MiletrieUniversity HospitalPoitiersFrance
| | - Elodie Dindinnaud
- Department of Biology, CHU La MiletrieUniversity HospitalPoitiersFrance
| | | | - Anna Raimbault
- Department of Biology, CHU La MiletrieUniversity HospitalPoitiersFrance
| | | | - Xavier Troussard
- Department of Hematology, CHU Cote de NacreUniversity HospitalCaenFrance
| | - Cécile Tomowiak
- Department of Hematology and Cellular Therapy, and INSERM CIC1402CHU La Miletrie, University HospitalPoitiersFrance
| |
Collapse
|
3
|
Kreitman RJ, Arons E. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Rev 2022; 51:100888. [PMID: 34535326 DOI: 10.1016/j.blre.2021.100888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Revised: 08/26/2021] [Accepted: 08/31/2021] [Indexed: 02/06/2023]
Abstract
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1st-line and relapsed settings. BRAF inhibitors and Ibrutinib can achieve remission, but due to persistence of MRD, must be used chronically to prevent relapse. BRAF inhibition combined with Rituximab can achieve high MRD-free CR rates. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox is FDA-approved in the relapsed setting and is unique in achieving high MRD-free CR rates as a single-agent. Avoiding chemotherapy and rituximab may be important in ensuring both recovery from COVID-19 and successful COVID-19 vaccination, an area of continued investigation.
Collapse
|